

Retraction

Retraction of: Extracellular vesicle derived miR-544 downregulates expression of tumor suppressor promyelocytic leukemia zinc finger resulting in increased peritoneal metastasis in gastric cancer

Wencheng Kong¹, Xinchun Liu¹, Guang Yin¹, Sixin Zheng¹, Akao Zhu¹, Panpan Yu¹, Yuqiang Shan¹, Rongchao Ying¹, Jian Zhang¹

¹Department of General Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang Province, P.R. China

Correspondence to: Jian Zhang; email: zhangjianpw@163.com, <https://orcid.org/0000-0001-8246-8069>

Keywords: peritoneal metastasis, gastric cancer, PLZF, miR-544, extracellular vesicle

Original article: *Aging (Albany NY)* 2020; 12:24009–24022

PMID: [33221764](https://pubmed.ncbi.nlm.nih.gov/33221764/)

PMCID: [PMC7762464](https://pubmed.ncbi.nlm.nih.gov/PMC7762464/)

doi: [10.18632/aging.104082](https://doi.org/10.18632/aging.104082)

This article has been retracted: Aging has completed its investigation of this paper. Several concerns were raised about the paper, including duplications and overlaps with unrelated papers from different institutions, as well as the reuse of previously published data. Specifically, the GAPDH Western blot image in Figure 1B is identical to the b-actin image in Figure 3D of an unrelated, earlier published paper [1]. Similarly, the PLZF blot in Figure 6B matches the USF1 blot in Figure 5A of the same paper [1]. Furthermore, immunofluorescence images from Figure 3D were previously published in Figure 5K of [2] and Figure 5B of [3]. Article [3] also shares a transwell assay image in Figure 5B with a panel in Figure 3D. Additionally, transwell assay images from Figure 3 appear in earlier published papers [4–12]. The transwell assay images from Figure 7 duplicate those found in articles [13–15], all of which have already been retracted. We also identified three later published articles that utilized some of the transwell images from Figures 3 and 7 [16, 17], and immunofluorescent images from Figure 3D [18]. The Scientific Integrity office at Aging contacted the authors regarding these issues. Dr. Wencheng Kong, the first author, requested a correction but did not follow up. In light of these findings, the Editors decided to retract the paper. The authors were informed of this decision, but the Scientific Integrity office has not received an official retraction letter signed by all authors.

REFERENCES

- Guo J, Fang W, Chen X, Lin Y, Hu G, Wei J, Zhang X, Yang C, Li J. Upstream stimulating factor 1 suppresses autophagy and hepatic lipid droplet catabolism by activating mTOR. *FEBS Lett.* 2018; 592:2725–38. <https://doi.org/10.1002/1873-3468.13203> PMID: [30054905](https://pubmed.ncbi.nlm.nih.gov/30054905/)
- Fang W, Guo J, Cao Y, Wang S, Pang C, Li M, Dou L, Man Y, Huang X, Shen T, Li J. MicroRNA-20a-5p contributes to hepatic glycogen synthesis through targeting p63 to regulate p53 and PTEN expression. *J Cell Mol Med.* 2016; 20:1467–80. <https://doi.org/10.1111/jcmm.12835> PMID: [27019188](https://pubmed.ncbi.nlm.nih.gov/27019188/)
- Wang A, Zhang H, Wang J, Zhang S, Xu Z. MiR-519d targets HER3 and can be used as a potential serum biomarker for non-small cell lung cancer. *Aging (Albany NY).* 2020; 12:4866–78. <https://doi.org/10.18632/aging.102908> PMID: [32170048](https://pubmed.ncbi.nlm.nih.gov/32170048/)
Retraction in: *Aging (Albany NY).* 2025; 17:1581–2. <https://doi.org/10.18632/aging.206265> PMID: [40637751](https://pubmed.ncbi.nlm.nih.gov/40637751/)

4. Jiang Z, Song Q, Zeng R, Li J, Li J, Lin X, Chen X, Zhang J, Zheng Y. MicroRNA-218 inhibits EMT, migration and invasion by targeting SFMBT1 and DCUN1D1 in cervical cancer. *Oncotarget*. 2016; 7:45622–36.
<https://doi.org/10.18632/oncotarget.9850>
PMID:[27285984](#)
5. Li P, Wang H, Hou M, Li D, Bai H. Upstream stimulating factor1 (USF1) enhances the proliferation of glioblastoma stem cells mainly by activating the transcription of mucin13 (MUC13). *Pharmazie*. 2017; 72:98–102.
<https://doi.org/10.1691/ph.2017.6788>
PMID:[29441861](#)
6. Liu L, Yu D, Shi H, Li J, Meng L. Reduced lncRNA Aim enhances the malignant invasion of triple-negative breast cancer cells mainly by activating Wnt/ β -catenin/mTOR/PI3K signaling. *Pharmazie*. 2017; 72:599–603.
<https://doi.org/10.1691/ph.2017.7547>
PMID:[29441885](#)
7. Zhou P, Li X. Serum miR-338-5p has potential for use as a tumor marker for retinoblastoma. *Oncol Lett*. 2019; 18:307–13.
<https://doi.org/10.3892/ol.2019.10331>
PMID:[31289501](#)
Retraction in: *Oncol Lett*. 2024; 27:215. <https://doi.org/10.3892/ol.2024.14347>
PMID:[38572062](#)
8. Wang W, Yao S, Jiang H, Dong J, Cui X, Tian X, Guo Y, Zhang S. Upstream transcription factor 1 prompts malignancies of cervical cancer primarily by transcriptionally activating p65 expression. *Exp Ther Med*. 2018; 16:4415–22.
<https://doi.org/10.3892/etm.2018.6758>
PMID:[30542391](#)
Retraction in: *Exp Ther Med*. 2024; 28:342. <https://doi.org/10.3892/etm.2024.12631>
PMID:[39006458](#)
9. Wang W, Dong J, Wang M, Yao S, Tian X, Cui X, Fu S, Zhang S. miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met. *Oncol Lett*. 2018; 15:6131–6.
<https://doi.org/10.3892/ol.2018.8110>
PMID:[29616095](#)
Retraction in: *Oncol Lett*. 2024; 28:511. <https://doi.org/10.3892/ol.2024.14644>
PMID:[39268157](#)
10. Wang Y, He X, Wei Y, Liu L, Wang W, Li N. SRC-like adaptor protein negatively regulates Wnt signaling in intrahepatic cholangiocarcinoma. *Oncol Lett*. 2019; 17:2745–53.
<https://doi.org/10.3892/ol.2019.9901>
PMID:[30854048](#)
Retraction in: *Oncol Lett*. 2024; 28:559. <https://doi.org/10.3892/ol.2024.14692>
PMID:[39372663](#)
11. Cheng D, Fan J, Ma Y, Zhou Y, Qin K, Shi M, Yang J. LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. *Cell Biosci*. 2019; 9:28.
<https://doi.org/10.1186/s13578-019-0290-2>
PMID:[30949340](#)
Retraction in: *Cell Biosci*. 2023; 13:149. <https://doi.org/10.1186/s13578-023-01103-6>
PMID:[37580829](#)
12. Geng Z, Wang W, Chen H, Mao J, Li Z, Zhou J. Circ_0001667 promotes breast cancer cell proliferation and survival via Hippo signal pathway by regulating TAZ. *Cell Biosci*. 2019; 9:104.
<https://doi.org/10.1186/s13578-019-0359-y>
PMID:[31893023](#)
13. Tian F, Ding D, Li D. Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells. *Int J Oncol*. 2015; 46:2355–63.
<https://doi.org/10.3892/ijo.2015.2959>
PMID:[25872479](#)
Retraction in: *Int J Oncol*. 2023; 63:99. <https://doi.org/10.3892/ijo.2023.5547>
PMID:[37477139](#)

14. Mou S, Wang G, Ding D, Yu D, Pei Y, Teng S, Fu Q. Expression and function of PIM kinases in osteosarcoma. *Int J Oncol*. 2016; 49:2116–26.
<https://doi.org/10.3892/ijo.2016.3708>
PMID:[27826617](https://pubmed.ncbi.nlm.nih.gov/27826617/)
Retraction in: *Int J Oncol*. 2023; 63:129. <https://doi.org/10.3892/ijo.2023.5577>
PMID:[37800631](https://pubmed.ncbi.nlm.nih.gov/37800631/)
15. He M, Wang G, Jiang L, Qiu C, Li B, Wang J, Fu Y. miR-486 suppresses the development of osteosarcoma by regulating PKC- δ pathway. *Int J Oncol*. 2017; 50:1590–600.
<https://doi.org/10.3892/ijo.2017.3928>
PMID:[28339053](https://pubmed.ncbi.nlm.nih.gov/28339053/)
Retraction in: *Int J Oncol*. 2023; 63:109. <https://doi.org/10.3892/ijo.2023.5557>
PMID:[37594084](https://pubmed.ncbi.nlm.nih.gov/37594084/)
16. Yu R, Wang M, Wang M, Han L. Melittin suppresses growth and induces apoptosis of non-small-cell lung cancer cells via down-regulation of TGF- β -mediated ERK signal pathway. *Braz J Med Biol Res*. 2020; 54:e9017.
<https://doi.org/10.1590/1414-431X20209017>
PMID:[33331417](https://pubmed.ncbi.nlm.nih.gov/33331417/)
17. Xu Y, Guo B, Liu X, Tao K. miR-34a inhibits melanoma growth by targeting ZEB1. *Aging (Albany NY)*. 2021; 13:15538–47.
<https://doi.org/10.18632/aging.203114>
PMID:[34102608](https://pubmed.ncbi.nlm.nih.gov/34102608/)
Retraction in: *Aging (Albany NY)*. 2024; 16:13432–3. <https://doi.org/10.18632/aging.206155>
PMID:[39622559](https://pubmed.ncbi.nlm.nih.gov/39622559/)
18. Zhu X, Chen X, Qiu L, Zhu J, Wang J. Norcantharidin induces ferroptosis via the suppression of NRF2/HO-1 signaling in ovarian cancer cells. *Oncol Lett*. 2022; 24:359.
<https://doi.org/10.3892/ol.2022.13479>
PMID:[36168316](https://pubmed.ncbi.nlm.nih.gov/36168316/)
Retraction in: *Oncol Lett*. 2025; 29:129. <https://doi.org/10.3892/ol.2025.14861>
PMID:[39822938](https://pubmed.ncbi.nlm.nih.gov/39822938/)